TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Peritoneal Dialysis in Congestive Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Refractory Left Ventricular Congestive Heart Failure: LVEF \< 30%~* Diminished renal function: eGFR \< 60 ml/min~* Clinically volume overloaded (Dyspnoea (NYHA III-IV), edema, and/or ascites)~* Hospitalization for CHF during the last 6 months~* Patient is on optimal cardiologic medical therapy, which has been stable for more than 4 weeks~* Suitable for PD~Exclusion Criteria:~* Hypotension (SBP \< 100 mmHg / MAP \< 70) mmHg~* Instable AP or recent (\< 6 months) myocardial infarction.~* Contraindications for PD (e.g. visual handicap, social)~* Liver failure~* COPD Gold class IV~* Malignancy with life expectancy \< 2 years~* Non compliance~* No informed consent~* Poor mental health

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Care (Type: SHAM_COMPARATOR): None
- 2 Icodextrin PD changes / day (Type: ACTIVE_COMPARATOR): None
- 1 Icodextrin PD change/day (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hair-sparing Whole Brain Radiotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Brain metastases~* Age ≥ 18 years.~* Signed informed consent~* Recursive Partitioning Analysis (RPA) class III patients~* Recursive Partitioning Analysis (RPA) class I-II patients and \>3 brain metastases~* Patients with small cell lung cancer extended disease eligible for prophylactic Whole-Brain Radiotherapy (WBRT).~Exclusion Criteria:~* Previous whole brain radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Assisted Reproduction-MET-AR-study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling Rotterdam criteria for PCOS~* Infertility more than 1 year~* First or second cycle of IVF/ICSI treatment~* Age below 38 years at inclusion~* BMI below 28 kg/m3 at inclusion~* Willing to be randomised to 4 months metformin or placebo~* Signed written informed consent~Exclusion Criteria:~* Not suitable for starting dose 112.5 IE~* Basal FSH above 10 IU/L~* Known renal disease or s-creatinine above 110 umol/L~* Known liver disease or s-ALAT above 80 IU/L~* Known alcoholism or drug abuse~* Known diabetes mellitus or fasting plasma glucose above 7 mmol/L~* Corticosteroid treatment (oral)~* Treatment with cimetidine, anticoagulants, erythromycin or other macrolides~* Hyperprolactinemia (PRL above 700 mIU/L)~* Abnormal thyroid function tests~* Known congenital adrenal hyperplasia~* Androgen secreting tumours~* Cushing syndrome~* Metformin treatment within the last one month prior to screening~* Unfit to participate for any other reason

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 38 Years
- Healthy Volunteers: t

Study Arms:
- M: Metformin P: Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short Term Evaluation of SLIC Screw in Treatment of Scapholunate Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects willing and able to comprehend and sign Informed Consent~* Subjects who have received the SLIC screw as part of the treatment for scapholunate ligament repair or scapholunate reduction~* Subjects with acute scapholunate injury, classified with Garcia-Elias Stage 1-4, OR Geissler Stage 1-3~* Subjects \>18 years of age at the time of surgery~Exclusion Criteria:~* Subject diagnosed with chronic scapholunate injury~* Subjects who underwent previous scapholunate procedure on the study wrist before implantation of the SLIC Screw System~* Subjects with active or latent infection at the time of surgery~* Subjects with sepsis at the time of surgery~* Subjects diagnosed with osteoporosis at the time of surgery~* Subjects with insufficient quantity and/or quality of bone~* Subjects with cartilage degeneration on the bones at the time of surgery~* Subjects with absence of potential for soft tissue healing at time of surgery, as documented by the investigator.~* Female Subjects known to be pregnant~* Subjects who were unable to follow postoperative care instructions, specifically, activity levels~* Subjects who are unable or unwilling to return for postoperative study visits

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Value of Rituximab in Humoral Chronic Rejection After Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Renal allograft recipients at least 1 year after transplantation with GFR \> 25 ml/min x 1,73m2 (MDRD)~* Single organ recipients of renal allograft~* Patients who have provided informed consent~* Patients who are \>= 18 years of age~* Patients who have biopsy proven CAN with C4d+ deposits and/or plasma-cells and/or B-lymphocytes within the last 4 weeks before inclusion~* Patients who are treated with ACE/AT1 Blocker more than 1 week before inclusion~Exclusion Criteria:~* Patients who suffer from HIV infection~* Patients with a history of Hepatitis B~* Patients with Hepatitis C (active/chronic)~* Patients who have a contraindication for the use of rituximab, such as leukopenia or experienced infusion-related adverse events to former antibody treatment~* Patients who showed signs of acute cellular rejection in the biopsy~* Patient has a malignancy or history of malignancy within the last 5 years, except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully.~* Patient has a systemic infection requiring treatment.~* Female patients who are pregnant or lactating~* Patients who have any form of substance abuse, psychological illness or any other condition, which, in the opinion of the investigator, may interfere with the patient's ability to understand the requirements of the study.~* Patients who have a proteinuria \>4g/24h~* Patient is unlikely to comply with the visits scheduled in the protocol.~* Patient is simultaneously participating in another investigational drug study or has participated in such study within 28 days before entry in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Treatment with rituximab
- Arm 2 (Type: NO_INTERVENTION): Treatment without rituximab

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Baclofen for Smoking Cessation in a Non-Psychiatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults (18 years or older).~* Meet DSM-IV criteria for nicotine dependence,~* Smoke ≥10 cigarettes/day,~* Baseline FTND score ≥4, CO level ≥10,~* have had at least one failed quit attempt in the past and are motivated to quit within 30 days of initial intake.~* No previous use of medication for smoking cessation in 1 month prior to randomization.~* BMI between 15 and 40 inclusive.~Exclusion Criteria:~* Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder, or a current or past history of bipolar disorder or schizophrenia~* Have a past history of major depression, with historical evidence of suicidal or homicidal behaviour, or psychotic symptom,~* Have abused alcohol or other drugs of abuse (cocaine, opiates, benzodiazepines, etc) in 3 months prior to randomization~* Demonstrate serious medical conditions, unstable cardiovascular disease, significant blood abnormalities)~* Are pregnant, are trying to become pregnant or are currently breastfeeding~* Baclofen hypersensitivity .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Baclofen 30 mg/day (Type: ACTIVE_COMPARATOR): Baclofen medication
- Placebo pill (Type: PLACEBO_COMPARATOR): placebo pill
- Baclofen 60 mg/day (Type: ACTIVE_COMPARATOR): Baclofen medication high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aldosterone Antagonism and Microvascular Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 40-65 years~* Caucasian~* Waist circumference \> 102 cm (men)/\> 88 cm (women)~* Triglycerides \> 1.7 mmol/L~* High-normal blood pressure (office blood pressure: 130/85 - 139/89 mm Hg) or stage I hypertension (office blood pressure: 140/90 mm Hg - 159/99 mm Hg; 24h ABPM: 125/80 - 149/89 mm Hg)~Exclusion Criteria:~* Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, congestive heart failure, cardiac shunts, cardiac surgery, pulmonary hypertension, cardiac arrhythmias, family history of cardiac arrhythmias or sudden cardiac death)~* Diabetes mellitus/impaired glucose metabolism (fasting glucose values \> 5.6 mmol/L)~* Grade 2 or 3 hypertension (office blood pressure: \> 160/100 mm Hg; ABPM \> 150/90 mm Hg)~* Unstable or severe pulmonary disease~* Unstable or severe thyroid disorders~* Inflammatory diseases~* Alcohol use \> 2 U/day (women)/\> 3 U/day (men)~* Use of antihypertensive, lipid-lowering or glucose-lowering medications,~* Use of corticosteroids, medication known to inhibit or induce CYP3A4, lithium, and tricyclic antidepressants or antipsychotic medication, and regular use (weekly or several times a week) of NSAIDs~* Plasma potassium levels \< 3.2 mmol/L or \> 5 mmol/L~* eGFR \< 60 mL/min~* Impairment of hepatic function~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Eplerenone (Type: ACTIVE_COMPARATOR): Eplerenone 50 mg 1dd during four weeks
- Placebo (Type: PLACEBO_COMPARATOR): Eplerenone-matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ruptured saccular aneurysm repaired by neurosurgical clipping~2. Subarachnoid hemorrhage on computed tomography (CT) scan of grade 2-4 on the modified Fischer scale~3. WFNS grade 1 or 2 assessed during the Pre-randomization Phase. If WFNS grade 2, must not require an EVD prior to aneurysm repair~Exclusion Criteria:~1. Major complication during aneurysm repair such as, but not limited to, massive intraoperative hemorrhage, brain swelling, arterial occlusion or inability to secure the ruptured aneurysm~2. Angiographic vasospasm prior to randomization~3. Evidence of cerebral infarction with neurological deficit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- EG-1962 Group (Type: EXPERIMENTAL): 1 dose of intracisternal EG-1962 (nimodipine microparticles) 600 mg
- Enteral Nimodipine Group (Type: ACTIVE_COMPARATOR): Up to a total of 21 days of enteral nimodipine (including nimodipine received prior to randomization)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of UC at least three months prior to screening, and with a minimum disease extent of 15 cm from the anal verge~* Active mild-to-moderate UC~* Inadequate response to, loss of response to, or intolerance of, at least one of the following conventional therapies: 5-ASA compounds, corticosteroids, 6-mercaptopurine (6-MP) or azathioprine (AZA), anti-TNFα, anti-integrin or tofacitinib~Exclusion Criteria:~* Known history of Crohn's disease~* No previous history of treatment for UC (treatment-naïve)~* Subjects on steroid medication who are unable to have steroids tapered and be completely off steroids at least two weeks prior to screening~* Unable to stop steroid enemas or suppositories, or 5-ASA enemas or suppositories, at least two weeks prior to screening~* Subjects who have received any investigational or approved biologic therapy within eight weeks or five half-lives prior to screening (whichever is longer)~* Subjects who have received any investigational or approved non-biologic therapy, except for those specifically listed in the Permitted Concomitant Medications, for the treatment of underlying disease, within 30 days or five half-lives prior to screening (whichever is longer)~* Major gastrointestinal surgery (not including appendectomy or cholecystectomy) within two months before screening, or any history of total colectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (after placebo pre-treatment) (Type: PLACEBO_COMPARATOR): Once-daily dosing of Placebo (after placebo pre-treatment)
- SER-287 Induction Dosing (after vancomycin pre-treatment) (Type: EXPERIMENTAL): Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
- SER-287 Step-Down Induction Dosing (after vancomycin pre-treatment) (Type: EXPERIMENTAL): Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Quantitation of Left Ventricular Ejection Fraction as Part of F-18 FDG Whole Body PET/CT Scans For Tumor Staging

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing both FDG PET/CT scan and RNV within two weeks interval, whether for initial staging, restaging or to evaluate response to therapy.~* Patients who would consent to an additional 10-15 minutes acquisition of the gated images after completion of their FDG PET/CT study with the additional radiation exposure.~* Patients with regular heart rate.~Exclusion Criteria:~* Blood glucose level above 200 mg/dL.~* Irregular heart rate.~* An interval of less than 1 day between the FDG PET/CT scan and RNV.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT scan + NM cardiac scan (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have given written informed consent~2. Be at least 18 years of age and have full legal capacity~3. Be able to handle the appliance themselves or with help from caregiver (e.g. spouse)~4. Have an ileostomy with a diameter between 15 and 45 mm~5. Have had their ostomy for at least three months~6. Currently use a 1-piece flat product with open bag~7. Use minimum 1 product every second day.~8. Be suitable for participation in the investigation and for using a standard adhesive, flat base plate~9. Must use custom cut product~10. Accept to test two 1-piece products within the study~Exclusion Criteria:~1. Use irrigation during the study (flush the stoma with water)~2. Currently receiving or have within the past 2 months received radio- and/or chemotherapy~3. Currently receiving or have within the past month received systemic steroid or local treatment in the peristomal area~4. Are pregnant or breastfeeding~5. Participating in other interventional clinical investigations or have previously participated in this investigation~6. Has more than three days wear time

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- First Coloplast Test product; then Standard Care (see below) (Type: EXPERIMENTAL): The subjects are randomised to test Coloplast Test product first and thereafter test Standard Care.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation.
- First Standard Care (see below); Then coloplast test product (Type: EXPERIMENTAL): The subjects are randomised to test Standard care first and thereafter test Coloplast test product.~Standard Care is a collection of three different already marketed 1-piece flat ostomy appliances. These are Coloplast Sensura 1-piece; Hollister: Moderma 1-piece and B.Braun Flexima 1-piece.~The three Standard Care products were tested in a 1:1:1 randomisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: NanoSpectrometer Biomarker Discovery and Confirmation Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and over with diagnosed Stage 1 Lung Cancer (cases)~* Adults age 18 and over without Lung cancer (type 1 controls)~* Adults age 18 and over who live in the same environment as the cases (type 2 controls)~Exclusion Criteria N/A

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Stage 1 Lung Cancer (Case) (Type: None): These are the participants with identified stage 1 lung cancer.
- Type 1 Control (Type: None): These are participants who have similar clinical characteristics as our cases, but do not have any history of cancer.
- Type 2 Control (Type: None): These are housemates of the participants with stage 1 lung cancer (cases).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Woman undergoing cesarean delivery~* At least 18 years of age~Exclusion Criteria:~* Allergy to iodine containing solutions~* Planned cesarean hysterectomy~* Prisoner

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vag prep (Type: EXPERIMENTAL): Vagina cleansed prior to performing cesarean

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Market Clinical Experience Study of Sientra 207 Breast Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Is a candidate for primary or revision breast augmentation and is at least 22 years of age,~2. Agrees to Sientra study requirements and to comply with office follow-up visits at months 3, 6 and 12.~Exclusion Criteria:~1. Does not meet the Investigator's standard eligibility for breast augmentation or revision surgery~2. Surgeon is planning to use acellular dermal matrix (ADM) or surgical mesh and/or recommend postoperative massage.

- Gender: FEMALE
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Primary Augmentation (Type: None): Subjects undergoing general breast enlargement receiving Sientra Style 207 Silicone Gel Breast Implant.
- Revision Augmentation (Type: None): Subjects undergoing revision surgery with Sientra Style 207 Silicone Gel Breast Implant to revise or improve the result of a primary breast augmentation surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues